PainReform Acquires Majority Equity Interest in LayerBio to Advance OcuRing-K Technology

PainReform收购LayerBio多数股权以推进OcuRing-K技术发展

August 15, 2025

2025年8月15日

PainReform has announced the acquisition of a majority equity interest in LayerBio, with plans to advance the company’s OcuRing-K technology into its next clinical trial.

PainReform 宣布收购 LayerBio 的多数股权，计划推动该公司的眼科技术 OcuRing-K 进入下一个临床试验阶段。

OcuRing-K Technology and Its Application in Cataract Surgery

OcuRing-K技术及其在白内障手术中的应用

The OcuRing technology is a bioerodible sustained-release implant applied to the haptic of an intraocular lens (IOL) for use during cataract surgery. Once implanted, it delivers medications continuously to treat and prevent postoperative complications.

OcuRing技术是一种生物可降解的缓释植入物，应用于人工晶状体（IOL）的触觉部分，用于白内障手术期间。一旦植入，它会持续释放药物以治疗和预防术后并发症。

OcuRing-K is specifically designed to deliver ketorolac, an anti-inflammatory and analgesic drug, intra-surgically during cataract procedures.

OcuRing-K 专为在白内障手术过程中术中递送酮咯酸（一种抗炎和镇痛药物）而设计。

This “dropless” alternative aims to eliminate challenges associated with traditional post-surgical eye drop regimens, which can suffer from poor patient compliance, particularly among the elderly, along with inconsistent drug delivery and steroid-related risks such as elevated intraocular pressure and infection..

这种“无滴剂”的替代方案旨在消除与传统术后眼药水治疗方案相关的挑战，这些挑战可能包括患者依从性差（尤其是老年人）、药物递送不一致以及类固醇相关风险，如眼压升高和感染。

Leadership Commentary on the Acquisition

关于收购的领导评论

“This transaction has the potential to position PainReform at the forefront of non-opiate innovation in one of the most common and impactful surgical procedures worldwide,” said Ehud Geller, Executive Chairman and interim CEO of PainReform. “LayerBio’s OcuRing-K is not just a product candidate—it represents a platform technology with the potential to disrupt the way we manage ocular pain and inflammation after surgery.

“这笔交易有可能使PainReform在全世界最常见且影响最大的外科手术之一中，处于非阿片类创新的前沿，” PainReform执行主席兼临时首席执行官埃胡德·盖勒表示。“LayerBio的OcuRing-K不仅是一个候选产品——它代表了一种平台技术，有望颠覆术后眼部疼痛和炎症的管理方式。”

By addressing the ‘dropless’ wishes of the ophthalmic market, we can improve patient outcomes and simplify treatment for providers. We see tremendous promise not only in cataract surgery, but in expanding this technology across additional ophthalmic and surgical indications.”.

通过满足眼科市场对“无滴剂”的需求，我们可以改善患者的治疗效果，并简化医疗服务提供者的治疗流程。我们看到这项技术不仅在白内障手术中具有巨大的潜力，还可以扩展到更多眼科及其他外科适应症的应用中。

Continued Leadership at LayerBio

LayerBio的持续领导力

Following the acquisition, Ken Mandell, MD, PhD, current CEO of LayerBio, will continue in his role, guiding the company’s operations and product development initiatives.

收购完成后，LayerBio现任首席执行官肯·曼德尔（Ken Mandell），医学博士、哲学博士，将继续担任其职务，指导公司的运营和产品开发计划。

Potential Applications of the OcuRing Platform Beyond Cataract Surgery

OcuRing平台在白内障手术之外的潜在应用

The OcuRing platform can deliver various ophthalmic medications, including corticosteroids, antibiotics, and glaucoma therapies. Beyond cataract surgery, PainReform and LayerBio plan to explore applications in glaucoma, corneal transplants, and anti-infective treatments.

OcuRing 平台可以递送多种眼科药物，包括皮质类固醇、抗生素和青光眼治疗药物。除了白内障手术之外，PainReform 和 LayerBio 还计划探索其在青光眼、角膜移植和抗感染治疗中的应用。